ProG-Phen®

Introduction:

Pro G Phen® is an innovative ingredient standardized in polyphenols and naringin based on natural extracts of Propolis MED® and Grapefruit which enhances the synergy of Propolis and Grapefruit.

The high concentration of Polyphenols > 40% tot. Polyphenols HLPC-UV-ES-MS (15-20% NARANGIN HPLC ES MS) guarantee a strong activity as: **Anti-inflammatory, antioxidant, antibacterial, bacteriostatic, antimycotic and antiviral properties proven by several vitro/vivo and clinical studies for different kind of applications.**

Thanks to the high dosage in Total Polyphenols, ProG-Phen® can prevent infection and inflammation status even with low dosage in the formulation.

The standardization and characterization of M.E.D.® allows to ensure to our customers the same quality and activity in every batch.

Applications:

- Prevention and treatment **Upper respiratory tract infections (URTI)**
- **Intimate care:** Prevention of urinary tract infection (UTI) and infection of vaginal mucosae
- **Antiaging** from polluting environmental sources
- **Oral care**: ProG-Phen® is active against the bacteria that causes for example plaque, halitosis, caries and periodontitis.

Available in two versions, POWDER microencapsulated in Arabic Gum and LIQUID hydrogliceric form, ProG-Phen® is **suitable for many applications in different proposal of mg/ml formulations.**

Composition in Polyphenols / Naringin

Polyphenols Complex	**Naringin**
- Powder: > 40%	15-25%
- Fluid Extract: > 20mg/ml	>1 mg/ml

Formulations:

Suitable for different galenic forms:

- vaginal ovules and capsules
- gel
- cream
- vaginal douche and soap detergent
- toothpaste
- mouthwash
- chewing gum
- labial stick
- oral and nasal spray
- syrup

Orientative Dosages:

- **Upper respiratory tract infections in adult:**

- 20mg - 37.5mg of ProG-Phen® Powder

- 0.4ml - 0.75ml ProG-Phen® Hydroglyceric

- **Upper respiratory tract infections in children:**

- 12.5mg - 18.75mg of ProG-Phen® Powder

- 0.25ml - 0.375ml ProG-Phen® Hydroglyceric

- **Urinary tract infections:**

- 20mg - 37.5mg oral/daily of ProG-Phen® Powder

- 0.4ml - 0.75 ml ProG-Phen® Hydroglyceric

Bibliography:

Volpi N, Bergonzini G. Analysis of flavonoids from propolis by on-line HPLC-electrospray mass spectrometry. J Pharm Biomed Anal. 2006 Sep 26;42(3):354-61. doi: 10.1016/j.jpba.2006.04.017. Epub 2006 Jun 9. PMID: 16762525.

Galeotti F, Maccari F, Fachini A, Volpi N. Chemical Composition and Antioxidant Activity of Propolis Prepared in Different Forms and in Different Solvents Useful for Finished Products. Foods. 2018 Mar 19;7(3):41. doi: 10.3390/foods7030041. PMID: 29562665; PMCID: PMC5867556.

da Silva LM, de Souza P, Jaouni SKA, Harakeh S, Golbabapour S, de Andrade SF. Propolis and Its Potential to Treat Gastrointestinal Disorders. Evid Based Complement Alternat Med. 2018 Mar 15;2018:2035820. doi: 10.1155/2018/2035820. PMID: 29736177; PMCID: PMC5875067.

Ota C, Unterkircher C, Fantinato V, Shimizu MT. Antifungal activity of propolis on different species of Candida. Mycoses. 2001 Nov;44(9-10):375-8. doi: 10.1046/j.1439-0507.2001.00671.x. PMID: 11766101.

Soumaya Touzani,1 Walaa Embaslat,2 Hamada Imtara ,1,3 Abdalsalam Kmail,3 Sleman Kadan,3 Hilal Zaid ,3 Ilham ElArabi,1 Lyoussi Badiaa ,1 and Bashar Saad 3In Vitro Evaluation of the Potential Use of Propolis as a Multitarget Therapeutic Product: Physicochemical Properties, Chemical Composition, and Immunomodulatory, Antibacterial, and Anticancer Properties.

Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol. 2011 Jan 27;133(2):253-60. doi: 10.1016/j.jep.2010.10.032. Epub 2010 Oct 21. PMID: 20970490.